{"id":57335,"date":"2024-02-27T17:37:55","date_gmt":"2024-02-27T17:37:55","guid":{"rendered":"https:\/\/medsname.com\/ocivox\/"},"modified":"2026-04-30T10:24:28","modified_gmt":"2026-04-30T10:24:28","slug":"ocivox","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/ocivox\/","title":{"rendered":"Ocivox"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Rychl\u00e1 odpov\u011b\u010f<\/h3>\n

Ocivox (Fluvoxamine maleate 50 \/ 100 mg) is a selective serotonin reuptake inhibitor used for depression, anxiety, and related disorders. Onset of antidepressant effect is gradual \u2014 4\u20136 weeks for a fair trial.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Ocivox at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a> \u2014 20pracovn\u00edchdenn\u00ed lh\u016fta pro doru\u010den\u00ed, nebo v\u00e1m z\u00e1silku zdarma p\u0159epo\u0161leme \u2014 a oprav\u0148uje v\u00e1s k \u00fa\u010dasti v na\u0161em v\u011brnostn\u00edm programu<\/a>. Dod\u00e1v\u00e1me do v\u011bt\u0161iny zem\u00ed po cel\u00e9m sv\u011bt\u011b.<\/p>\n

How Ocivox works<\/h2>\n

Ocivox<\/strong> is a Fluvoxamine maleate-containing SSRI tablet supplied by Sun Pharma. Available strengths: 50 \/ 100 mg<\/strong>. U\u017e\u00edvejte s j\u00eddlem nebo bez j\u00eddla, ve stejnou dobu ka\u017ed\u00fd den pro stabiln\u00ed hladinu v plazm\u011b.<\/p>\n

SSRI blokuj\u00ed zp\u011btn\u00e9 vychyt\u00e1v\u00e1n\u00ed serotoninu (5-HT) na presynaptick\u00e9m serotoninov\u00e9m transport\u00e9ru (SERT), \u010d\u00edm\u017e zvy\u0161uj\u00ed dostupnost synaptick\u00e9ho serotoninu. Terapeutick\u00fd \u00fa\u010dinek se objevuje se zpo\u017ed\u011bn\u00edm 2\u20136 t\u00fddn\u016f po blok\u00e1d\u011b transport\u00e9ru \u2014 toto zpo\u017ed\u011bn\u00ed odr\u00e1\u017e\u00ed n\u00e1sledn\u00e9 adaptace v citlivosti 5-HT autoreceptor\u016f, expresi BDNF a neurogenezi v hippocampu, nikoli p\u0159\u00edm\u00e9 \u00fa\u010dinky na receptory. Pacienti, kte\u0159\u00ed po 2 t\u00fddnech \u201cnec\u00edt\u00ed nic\u201d, by nem\u011bli l\u00e9\u010dbu p\u0159ed\u010dasn\u011b ukon\u010dovat; vyhodno\u0165te odpov\u011b\u010f po 4\u20136 t\u00fddnech adekv\u00e1tn\u00ed d\u00e1vky.<\/p>\n

Fluvoxamine is often the preferred SSRI for OCD<\/strong>, particularly in paediatrics (FDA-approved from age 8). It has minimal sexual side effects relative to other SSRIs and tends to be sedating \u2014 bedtime dosing helps both insomnia and tolerability. The “fluvoxamine for COVID-19” hypothesis from 2020\u201322 (sigma-1 anti-inflammatory action) remains unproven and should not influence prescribing decisions.<\/p>\n

Indikace a d\u00e1vkov\u00e1n\u00ed<\/h2>\n\n\n\n\n\n\n\n\n
Indikace<\/th>\nPo\u010d\u00e1te\u010dn\u00ed d\u00e1vka<\/th>\nC\u00edlov\u00e1 d\u00e1vka<\/th>\nMaxim\u00e1ln\u00ed d\u00e1vka<\/th>\n<\/tr>\n<\/thead>\n
OCD (adult)<\/td>\n50 mg p\u0159ed span\u00edm<\/td>\n100\u2013300 mg\/den<\/td>\n300 mg (split >100)<\/td>\n<\/tr>\n
OCD (paediatric \u22658 y)<\/td>\n25 mg p\u0159ed span\u00edm<\/td>\n50\u2013200 mg\/day<\/td>\n200 mg<\/td>\n<\/tr>\n
Social anxiety \/ GAD (off-label)<\/td>\n50 mg p\u0159ed span\u00edm<\/td>\n100\u2013200 mg\/den<\/td>\n300 mg<\/td>\n<\/tr>\n
Hepatic impairment \/ older adults<\/td>\n25 mg p\u0159ed span\u00edm<\/td>\n50\u2013100 mg\/day<\/td>\ndle sn\u00e1\u0161enlivosti<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

D\u016fle\u017eit\u00e9 bezpe\u010dnostn\u00ed aspekty<\/h2>\n
\nStrong CYP1A2 + CYP2C19 inhibitor \u2014 interaction-dense<\/strong><\/p>\n

Fluvoxamine has the broadest and most clinically important CYP-inhibition profile of any SSRI<\/strong>. Significantly raises levels of: theophylline (toxicity at low doses), tizanidine (severe hypotension \u2014 absolute contraindication), clozapine (4\u201310\u00d7 concentration rise; reduce clozapine dose by half), olanzapine, melatonin, caffeine (insomnia, palpitations), warfarin, propranolol, methadone, ramelteon. Always check for interactions before adding fluvoxamine to an existing regimen.<\/p>\n<\/div>\n

\n\u010cern\u00e9 varov\u00e1n\u00ed ohledn\u011b sebevra\u017eednosti (u osob do 25 let)<\/strong><\/p>\n

V\u0161echna SSRI nesou varov\u00e1n\u00ed FDA (\u010dern\u00fd r\u00e1me\u010dek) ohledn\u011b zv\u00fd\u0161en\u00e9ho rizika sebevra\u017eedn\u00fdch my\u0161lenek u pacient\u016f mlad\u0161\u00edch 25 let, zejm\u00e9na v prvn\u00edch 4 t\u00fddnech a p\u0159i zm\u011bn\u00e1ch d\u00e1vkov\u00e1n\u00ed. To neznamen\u00e1, ne<\/em> \u017ee SSRI jsou pro mlad\u00e9 lidi celkov\u011b \u0161kodliv\u00e1 \u2014 metaanal\u00fdzy ukazuj\u00ed \u010dist\u00fd benefit \u2014 ale vy\u017eaduje to pe\u010dliv\u00e9 klinick\u00e9 sledov\u00e1n\u00ed b\u011bhem zah\u00e1jen\u00ed l\u00e9\u010dby a titrace u dosp\u00edvaj\u00edc\u00edch a mlad\u00fdch dosp\u011bl\u00fdch.<\/p>\n<\/div>\n

\nSerotoninov\u00fd syndrom<\/strong><\/p>\n

Combining Ocivox with other serotonergic agents can cause serotonin syndrome (tremor, hyperreflexia, clonus, hyperthermia, agitation). Avoid concurrent: MAOIs (14-day washout each direction; fluoxetine needs 5 weeks), tramadol, pethidine, dextromethorphan, linezolid, methylene blue, St John’s wort, MDMA. Triptan + SSRI is generally tolerated for migraine \u2014 the absolute risk is low.<\/p>\n<\/div>\n

\u010cast\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky<\/h2>\n